Company Analysis

RenovoRx, Inc. (RNXT)

Nasdaq: RNXT · Pharmaceutical Preparations · Mountain View, CA · filing with the SEC since 2013
Grade4.3
◀ Past 3.5● Present 3.7▶ Future 5.3
4 est.

Who runs RenovoRx, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Bagai Shaun
Chief Executive Officer. First filing Aug 2021, latest Apr 7, 2026, 9 filings in all.
Officers reporting now
5
of 9 people with a filing in the last fifteen months
Directors reporting now
4
14 people on the record since 2021
Officerssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Voll MarkChief Financial OfficerMar 2026Sep 15, 2026none
Bagai ShaunChief Executive OfficerAug 2021Apr 7, 2026none
Agah RamtinChief Medical OfficerAug 2021Apr 7, 2026none
Gentry LeesaChief Clinical OfficerMar 2024Apr 7, 2026none
Kocak RonVP, Controller and PAOFeb 2024Jul 3, 2025none
Directorssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameRoleFirst filingLatest filingSales, 12 months
Macfarlane K. AngeladirectorAug 2021Oct 2, 2026none
Marton LaurencedirectorAug 2021Oct 2, 2026none
Ryan Una SdirectorAug 2021Oct 2, 2026none
Spiegel Robert J.directorApr 2023Oct 2, 2026none
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RNXT · research, not advice